Recombinant Human CD83 Protein, C-His-tagged

• Cat.No.: CD83-180H
• Product Overview: Recombinant Human CD83 Protein with C-His tag was expressed in E. coli.

Specification

• Description: CD83 is a single-transmembrane protein with a calculated molecular weight (MW) of 23 kDa, but due to heavy and differential glycosylation, its apparent MW ranges from 23 to 70 kDa. CD83 is predominantly expressed on mature dendritic cells (DCs) and has been used as a DC activation/maturation marker as its increased expression is correlated with upregulation of HLA class II antigen expression on DCs. CD83 is also expressed at a low level on lymphocytes and is upregulated upon lymphocyte activation. Thymic epithelial cells also express CD83, which is required for normal CD4+ T cell development. CD83 is also expressed as a soluble form (sCD83) that can be found in serum of healthy adults. sCD83 has been shown to negatively regulate immune response by lymphocytes.
• Source: E. coli
• Species: Human
• Tag: His
• Molecular Mass: ~14 kDa
• AA Sequence: TPEVKVACSEDVDLPCTAPWDPQVP YTVSWVKLLEGGEERMETPQEDHLR GQHYHQKGQNGSFDAPNERPYSLKI RNTTSCNSGTYRCTLQDPDGQRNLS GKVILRVTGCPAQRKEETFKKYRAE
• Purity: Transferred into competent cells and the supernatant was purified by NI column affinity chromatography and the purity is > 85% (by SDS-PAGE).
• Notes: For research use only, not for use in diagnostic procedure.
• Storage: Store at 4 centigrade short term. Aliquot and store at -20 centigrade long term. Avoid freeze-thaw cycles.
• Concentration: ≥0.5 mg/mL
• Storage Buffer: PBS, 4M Urea, pH7.4

Gene Information

• Gene Name: CD83 CD83 molecule [ Homo sapiens (human) ]
• Official Symbol: CD83
• Synonyms: CD83; CD83 molecule; CD83 antigen (activated B lymphocytes, immunoglobulin superfamily) , CD83 molecule; CD83 antigen; BL11; HB15; hCD83; B-cell activation protein; cell surface protein HB15; cell-surface glycoprotein; CD83 antigen (activated B lymphocytes, immunoglobulin superfamily)
• Gene ID: 9308
• mRNA Refseq: NM_001040280
• Protein Refseq: NP_001035370
• MIM: 604534
• UniProt ID: Q01151

Reviews

03/16/2021

The experimental conditions are wide, and the experimental results are accurate and reproducible.

08/24/2020

The resulting strips are clear and bright, which greatly exceeds the expected results.

06/10/2020

CD83 activity is maintained for a very long time and can be maintained for a long time, which is very stable and reliable.

Q&As

Could CD83 be a target for immunotherapy?

Yes, CD83 can be targeted as immunotherapy. Immunotherapy for CD83 has been explored in several clinical trials with some efficacy.

Are there population differences in CD83 treatment?

It is unclear whether there is a population difference in CD83 treatment. However, due to factors such as individual differences and genetic polymorphisms, different populations may respond differently to treatment. Therefore, population-specific treatment strategies may need to be individually adapted and optimized.

What are possible aspects of future research on CD83?

Future research on CD83 may involve more in-depth molecular mechanism studies, optimization and improvement of CD83-based immunotherapy strategies, and research on combination with other immunotherapies or drugs.

Is there a relationship between CD83 and other immune checkpoint molecules?

CD83 interacts and regulates with other immune checkpoint molecules. Together, they are involved in the regulation of the immune response.

Is CD83 expression regulated by other molecules?

Yes, CD83 expression is regulated by a variety of molecules, including cytokines, transcription factors, and epigenetic modifications.

What is the therapeutic approach for CD83?

Current treatments for CD83 mainly include immunotherapy and gene therapy. Immunotherapy against CD83 works primarily by modulating the function of dendritic cells and T cells.